145 related articles for article (PubMed ID: 7531332)
21. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells.
Zhang K; Baeckström D; Brevinge H; Hansson GC
J Cell Biochem; 1996 Mar; 60(4):538-49. PubMed ID: 8707893
[TBL] [Abstract][Full Text] [Related]
22. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.
Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T
Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821
[TBL] [Abstract][Full Text] [Related]
23. Novel serum tumor marker, RCAS1, in pancreatic diseases.
Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
[TBL] [Abstract][Full Text] [Related]
24. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer.
Sunagawa Y; Yamada S; Sato Y; Morimoto D; Sonohara F; Takami H; Inokawa Y; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Ann Surg Oncol; 2020 Jun; 27(6):2081-2089. PubMed ID: 31673938
[TBL] [Abstract][Full Text] [Related]
25. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast-cancer patients.
Sikut R; Zhang K; Baeckström D; Hansson GC
Int J Cancer; 1996 May; 66(5):617-23. PubMed ID: 8647622
[TBL] [Abstract][Full Text] [Related]
26. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. A retrospective study.
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Cancer; 1991 Jul; 68(1):149-52. PubMed ID: 2049735
[TBL] [Abstract][Full Text] [Related]
27. Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation.
Partyka K; Maupin KA; Brand RE; Haab BB
Proteomics; 2012 Jul; 12(13):2212-20. PubMed ID: 22623153
[TBL] [Abstract][Full Text] [Related]
28. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.
Narimatsu H; Iwasaki H; Nakayama F; Ikehara Y; Kudo T; Nishihara S; Sugano K; Okura H; Fujita S; Hirohashi S
Cancer Res; 1998 Feb; 58(3):512-8. PubMed ID: 9458099
[TBL] [Abstract][Full Text] [Related]
29. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
[TBL] [Abstract][Full Text] [Related]
30. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
[TBL] [Abstract][Full Text] [Related]
31. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer.
Omiya K; Oba A; Inoue Y; Kobayashi K; Wu YHA; Ono Y; Sato T; Sasaki T; Ozaka M; Sasahira N; Ito H; Saiura A; Takahashi Y
Ann Surg; 2023 Jun; 277(6):e1278-e1283. PubMed ID: 35081567
[TBL] [Abstract][Full Text] [Related]
32. [Monoclonal antibodies directed to human lung cancer].
Kannagi R; Miyake M; Itai S; Naito M; Hashimoto K
Rinsho Kyobu Geka; 1989 Feb; 9(1):19-28. PubMed ID: 9301894
[TBL] [Abstract][Full Text] [Related]
33. Characterization of new pancreatic cancer-reactive monoclonal antibodies directed against purified mucin.
Ho JJ; Bi N; Yan PS; Yuan M; Norton KA; Kim YS
Cancer Res; 1991 Jan; 51(1):372-80. PubMed ID: 1703039
[TBL] [Abstract][Full Text] [Related]
34. Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA50.
Kawa S; Kato M; Oguchi H; Kobayashi T; Hsue GL; Koiwai T; Aoki Y; Furuta S; Kanai M
Scand J Gastroenterol; 1991 Dec; 26(12):1307-18. PubMed ID: 1662409
[TBL] [Abstract][Full Text] [Related]
35. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G; Guo M; Jin K; Liu Z; Liu C; Cheng H; Lu Y; Long J; Liu L; Xu J; Ni Q; Yu X
Pancreatology; 2016; 16(6):1057-1062. PubMed ID: 27692554
[TBL] [Abstract][Full Text] [Related]
36. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients.
Chung YS; Ho JJ; Kim YS; Tanaka H; Nakata B; Hiura A; Motoyoshi H; Satake K; Umeyama K
Cancer; 1987 Oct; 60(7):1636-43. PubMed ID: 3476183
[TBL] [Abstract][Full Text] [Related]
37. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
38. Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme.
Narimatsu H; Iwasaki H; Nishihara S; Kimura H; Kudo T; Yamauchi Y; Hirohashi S
Cancer Res; 1996 Jan; 56(2):330-8. PubMed ID: 8542588
[TBL] [Abstract][Full Text] [Related]
39. CA 19-9: Biochemical and Clinical Aspects.
Scarà S; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
[TBL] [Abstract][Full Text] [Related]
40. New derivatives of reducing oligosaccharides and their use in enzymatic reactions: efficient synthesis of sialyl Lewis a and sialyl dimeric Lewis x glycoconjugates.
Bårström M; Bengtsson M; Blixt O; Norberg T
Carbohydr Res; 2000 Oct; 328(4):525-31. PubMed ID: 11093708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
